Welcome to our dedicated page for Ardelyx news (Ticker: ARDX), a resource for investors and traders seeking the latest updates and insights on Ardelyx stock.
Ardelyx, Inc. develops and commercializes biopharmaceutical products built around tenapanor and NHE3 inhibition. The company has two U.S.-approved commercial products: IBSRELA for adults with irritable bowel syndrome with constipation and XPHOZAH to reduce serum phosphorus in adults with chronic kidney disease on dialysis when phosphate binder therapy is inadequate or not tolerated.
Ardelyx news commonly covers product revenue, prescription trends, business updates, scientific meeting presentations, and clinical analyses tied to XPHOZAH and IBSRELA. Recurring developments also include pipeline work in chronic idiopathic constipation and next-generation NHE3 inhibition, commercialization with partners outside the United States, patient advocacy programs, and executive leadership changes in medical, legal, finance, and compliance functions.
Ardelyx (Nasdaq: ARDX) announced the five recipients of the 2026 Derek Forfang Patient Advocate Award on March 12, 2026. Honorees Edward Drake II, Markesha Grayson, Timmy Nelson, Pesh Patel and Glenda Roberts were selected for sustained advocacy on behalf of people with chronic kidney disease.
Recipients will be honored at the National Kidney Foundation Spring Clinical Meetings in New Orleans; the award recognizes contributions in outreach, policy, education and patient-centered research engagement.
Ardelyx (Nasdaq: ARDX) announced publication of a peer‑reviewed post‑hoc analysis titled “Tenapanor is associated with earlier and sustained symptom relief in IBS‑C” in Therapeutic Advances in Gastroenterology.
Pooled data from one Phase 2b and two Phase 3 trials showed increased bowel movement frequency by 2 weeks, meaningful abdominal symptom relief by 4–5 weeks, and greater likelihood of sustained benefit through 12 weeks. No new safety signals were reported; transient mild‑to‑moderate diarrhea was most common.
Ardelyx (Nasdaq: ARDX) announced participation in two investor events in Miami the week of March 10, 2026: the Leerink Partners 2026 Global Healthcare Conference and the Jefferies 2026 Biotech on the Beach Summit.
The company will present at Leerink on March 10 at 4:20 p.m. ET with 1x1 meetings on March 10 and 11. A live webcast will be available on the Events and Presentations page at ir.ardelyx.com; a replay will be hosted for 30 days after the Leerink presentation.
Ardelyx (Nasdaq: ARDX) announced a multi-year partnership with the LPGA to raise awareness and reduce stigma around digestive health, specifically irritable bowel syndrome with constipation (IBS-C).
The collaboration will use LPGA platforms, digital content, player ambassadors and onsite activations throughout the 2026 season to educate and connect patients.
Ardelyx (Nasdaq: ARDX) reported full-year 2025 results with total revenue of $407.3 million and IBSRELA revenue of $274.2 million (73% YoY). XPHOZAH generated $103.6 million. Cash and short-term investments were $264.7 million as of December 31, 2025. The company launched a Phase 3 CIC trial (ACCEL) and expects FDA submission timing contingent on results.
Management guided 2026 IBSRELA revenue to $410–$430 million and XPHOZAH to $110–$120 million; net loss was $61.6 million for 2025.
Ardelyx (Nasdaq: ARDX) will report full year and fourth quarter 2025 results and host a conference call on Thursday, February 19, 2026 at 4:30 p.m. Eastern Time. The call will feature the executive leadership team and include a business update.
Live audio will be webcast via the Investors section at the company's website and archived for replay for 30 days.
Ardelyx (Nasdaq: ARDX) announced that the USPTO issued U.S. Patent No. 12,539,299 titled “Oral Formulations of Tenapanor”, covering the commercial formulations of IBSRELA and XPHOZAH, with an expiration date of November 26, 2042.
The company said it will submit the patent for listing in the FDA Orange Book. The November 26, 2042 expiry reflects a Patent Term Adjustment due to USPTO delays and updates prior communications.
Ardelyx (Nasdaq: ARDX) announced the first patient has been dosed in ACCEL, a Phase 3 trial evaluating IBSRELA (tenapanor) for chronic idiopathic constipation (CIC).
ACCEL is randomized, double-blind, placebo-controlled, plans ~700 patients, twice-daily dosing for 26 weeks, enrollment through 2026 and topline data expected in H2 2027. Safety notes include diarrhea rates and a pediatric dehydration boxed warning.
Ardelyx (Nasdaq: ARDX) reported preliminary, unaudited 2025 product revenue of approximately $378 million with IBSRELA generating about $274 million/b in 2025, a 73% increase vs. 2024 and ~$87 million in Q4. XPHOZAH revenue was ~
Ardelyx (Nasdaq: ARDX) presented real-world and clinical analyses of XPHOZAH (tenapanor) at ASN Kidney Week on November 7, 2025. Key findings: real-world initiators experienced an average serum phosphate reduction of ~1.0 mg/dL, with 45.3% of patients reducing ≥1 mg/dL and 25.1% reducing ≥2 mg/dL over a 120-day follow-up. A patient survey reported 63% felt phosphate levels were better and 69% reported improved outlook on control. Additional posters showed improved bowel movements in ESKD patients and a Japan cost-effectiveness analysis meeting a 5 million JPY willingness-to-pay threshold.